Lentiviral vector targeting

Current Topics in Microbiology and Immunology

Volumn 261, Issue , 2002, Pages 143-163

  Larochelle, A ^a   Peng, K W ^a   Russell, S J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; VIRUS ENVELOPE PROTEIN;

DNA MODIFICATION; GENE TARGETING; GENE THERAPY; HOST RANGE; LENTIVIRINAE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; VIRUS TRANSCRIPTION;

LENTIVIRUS;

EID: 0036206148     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-56114-6_7     Document Type: Review

References (88)

1. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
2. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity
3. Regulatable systems: Applications in gene therapy and replicating viruses
4. Efficient infection mediated by viral receptors incorporated into retroviral particles
5. Targeting retroviral vectors to CD34-expressing cells: Binding to CD34 does not catalyze virus-cell fusion
6. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
7. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types
8. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
9. In vivo selection of protease cleavage sites from retrovirus display libraries
10. Vesicular stomatitis virus G glyco-protein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells
11. Gene therapy of human severe combined immunodeficiency (SC1D)-X1 disease
12. Modification of retroviraI tropism by display of 1GF-I
13. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses
14. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins
15. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer
16. Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies
17. Retroviral retargeting by envelopes expressing an N-terminal binding domain
18. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum
19. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus
20. Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes
21. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library
22. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker
23. Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution
24. A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: Recovery of an anti-HIV mouse/human pseudotype retrovirus
25. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells
26. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: Targeting of a cytotoxic gene by ligand display
27. Antibody-mediated binding of a murine ecotropic Moloney retroviral vector to human cells allows internalization but not the establishment of the proviral state
28. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein
29. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor
30. Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector
31. Ligand-directed retroviral targeting of human breast cancer cells
32. Transduction potential of human retroviruses in highly proliferating small-cell lung cancer cells as well as non-proliferating hematopoietic stem cells
33. Inducible control of gene expression: Prospects for gene therapy
34. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses
35. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies
36. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
37. A packaging cell line for lentivirus vectors
38. Lentiviral vectors: Regulated gene expression
39. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
40. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system
41. Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody
42. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range
43. Packaging system for rapid production of murine leukemia virus vectors with variable tropism
44. Incorporation of tumor vasculature targeting motifs into Moloney murine leukaemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells
45. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe
46. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins
47. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope
48. Retrovirus targeting by tropism restriction to melanoma cells
49. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1
50. Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins
51. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin
52. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells
53. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus
54. Targeted vectors for gene therapy
55. Progress in transcriptionally targeted and regulatable vectors for genetic therapy
56. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector
57. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
58. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors
59. Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system
60. In vivo gene delivery and stable transduction of nondividing cells by a Icntiviral vector
61. Gene therapy: Designer promoters for tumour targeting
62. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes
63. Targeting of retroviral vectors through protease-substrate interactions
64. Sequences determining the pH dependence of viral entry are distinct from the host range-determining region of the murine ecotropic and amphotropic retrovirus envelope proteins
65. A gene delivery system activatable by disease-associated matrix metalloproteinases
66. Retroviral gene delivery system activatable by plasmin
67. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors
68. Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes
69. Transduction o nondividing cells using pseudotyped defective high-titer HIV type I particles
70. Production and concentration of pseudotyped HIV-1-based gene transfer vectors
71. Simian immunodeficiency virus vectors: Replication and pseudotyping
72. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
73. A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses
74. Retroviral vectors displaying functional antibody fragments
75. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection
76. Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins?
77. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein
78. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
79. Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping
80. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism
81. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1
82. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors
83. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU
84. Receptor co-operation in retrovirus entry: Recruitment of an auxiliary entry mechanism after retargeted binding
85. A murine cell line producing HTLV-I pseudotype virions carrying a selectable marker gene
86. Characterization of the prolinerich region of murine leukemia virus envelope protein
87. Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the gag and pol proteins of Moloney murine leukemia virus
88. Identification of the block in targeted retroviral-mediated gene transfer